Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of cilnidipine with or without tadalafil for severe secondary Raynaud's syndrome
ACTRN12621000459820Phase 2Completed
- Sponsor
- Aisa Pharma, Inc.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cilnidipine and tadalafil in Raynaud disease (6 arms), sponsored by Aisa Pharma, Inc. Primary endpoint: Percentage change from baseline in frequency of weekly Raynaud's phenomenon attacks. Started Jun 2021; status: completed.
02
Drugs
cilnidipinetadalafil
03
Conditions
Raynaud disease
Beyond the preview
Go deeper on ACTRN12621000459820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000459820.